María Natalia Gandur Quiroga: A significant advancement in bladder cancer treatment
María Natalia Gandur Quiroga shared on X/Twitter:
“The article ‘FGFR inhibition augments anti–PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression’ reveals a significant advancement in bladder cancer treatment.
- It shows that inhibiting Fibroblast Growth Factor Receptor (FGFR) enhances the effectiveness of anti-PD-1 therapy in mice with FGFR3-mutant bladder cancer, by halting the expansion of immunosuppressive regulatory T cells.
- This suggests a promising method to improve immunotherapy efficacy in certain bladder cancers.”
View the article.
Source: María Natalia Gandur Quiroga/X
Maria Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Instituto de Oncología Ángel H. Roffo in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies. Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023